Beckman Coulter has announced that it will be combining Agencourt Bioscience and the newly acquired Cogenics to Beckman Coulter Genomics.
Beckman Coulter has announced that it will be combining Agencourt Bioscience and the newly acquired Cogenics to form Beckman Coulter Genomics. The new company is expected to offer researchers a single genomic services resource with expanded global capabilities.
"Through the creation of Beckman Coulter Genomics, we have successfully brought together the industry's leading genomic service providers to offer our customers the highest quality data and analysis," said Richard Creager, PhD, Beckman Coulter group vice president of immunoassay, molecular diagnostics and genomic services, in a statement.
Services currently available through the new company are reported to include sequencing, sample preparation, genotyping, gene expression, biological efficiency and safety testing, with support for all levels of regulatory compliance, including Clinical Laboratory Improvement Amendments (CLIA).
The new company has offices throughout North America and Europe.
For more information about Beckman Coulter Genomics visit www.beckmangenomics.com, www.agencourt.com and www.cogenics.com
LCGC’s Year in Review: Highlights in Liquid Chromatography
December 20th 2024This collection of technical articles, interviews, and news pieces delves into the latest innovations in LC methods, including advance in high performance liquid chromatography (HPLC), ultrahigh-pressure liquid chromatography (UHPLC), liquid chromatography–mass spectrometry (LC–MS), and multidimensional LC.
Using LC-MS/MS to Measure Testosterone in Dried Blood Spots
December 19th 2024Testosterone measurements are typically performed using serum or plasma, but this presents several logistical challenges, especially for sample collection, storage, and transport. In a recently published article, Yehudah Gruenstein of the University of Miami explored key insights gained from dried blood spot assay validation for testosterone measurement.